# TB006 for Autism Spectrum Disorder

> **NCT06500637** · PHASE2 · RECRUITING · sponsor: **Rossignol Medical Center** · enrollment: 45 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** TB006

## Key facts

- **NCT ID:** NCT06500637
- **Lead sponsor:** Rossignol Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500637, "TB006 for Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06500637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*